Back to search results

Immune Profiling for Cancer Immunotherapy Response

This observational study is looking at how your immune system responds to cancer immunotherapy, specifically treatments like pembrolizumab, nivolumab, or ipilimumab. Researchers will collect blood samples before and during your treatment to see if certain immune markers (immune-methylation profiling and cytokine profiling) can predict how well you respond to therapy or if you experience side effects. You can join if you are an adult (18 years or older) with cancer who is receiving or will receive FDA-approved immunotherapy. The study aims to understand treatment response over 5 years. The current recruitment status is unclear.

Study design
This is an observational study planning to enroll 1500 participants. It is not a treatment study, but rather looks at information from patients already receiving immunotherapy.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your response to therapy will be measured for 5 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06116032

Immune Profiling for Cancer Immunotherapy Response

Recruiting
Not specifiedAges 18+Observational
Dartmouth-Hitchcock Medical Center
~1,500 participants
Updated 2025-12-16 on ClinicalTrials.gov
What's tested:Methylation Cytometry

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Response to therapy
Measured over 5 years

Conditions

Cancer
Tumor, Solid
Hematologic Malignancy
Blood Cancer

Explore related trials

Hematologic NeoplasmSolid Neoplasm

NCT06116032

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Dartmouth-Hitchcock Medical Center

    Lebanon, New Hampshirestudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Brock C Christensen, PhD · PRINCIPAL_INVESTIGATOR · Dartmouth College

Who to contact

Brock C Christensen, PhD
[email protected]
603-650-1827
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Cancer patients receiving or will receive immunotherapy under FDA- approved indication (e.g. checkpoint inhibitor therapy with pembrolizumab, nivolumab, or ipilimumab, or cellular immunotherapy).
Participants are eligible regardless of the type of prior therapy (i.e. prior immunotherapy treated participants can be included).

Exclusion

Pregnant women/fetuses/neonates
Prisoners
Decision-impaired individuals

What this trial measures

  • Response to therapy5 years

    The investigators will employ iRECIST, and outcome criteria will be clinically evaluated and include the primary endpoints of progression (non-responders) or response, with patients followed up every month for 6 months (or until death, loss to follow-up, or withdrawal of consent), judged according to the objective response rate (ORR) assessed using iRECIST.